AMANDA CARLOCK: Open Payments
NPI 1639957681 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$936 in 53 payments from 14 companies in 2025. Trend: 2023 $111 · 2024 $818 · 2025 $936
Food & beverage: $936
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $397 |
| Otsuka America Pharmaceutical, Inc. | 4 | $88 |
| ABBVIE INC. | 3 | $63 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| Supernus Pharmaceuticals, Inc. | 2 | $41 |
| Corium, LLC | 3 | $40 |
| Almatica Pharma LLC | 2 | $39 |
| Janssen Pharmaceuticals, Inc | 2 | $39 |
Products named: CAPLYTA, REXULTI, VRAYLAR, Auvelity, FANAPT, COBENFY, Qelbree, Azstarys.
Industry payments across IN — which companies pay providers there.
